Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every 4 weeks. IL-2 was administered according to a groupwise dose escalation schedule (group A, 3 x 10(4); group B, 3 x 10(5);...

Descripción completa

Detalles Bibliográficos
Autores principales: Goey, S. H., Eggermont, A. M., Punt, C. J., Slingerland, R., Gratama, J. W., Oosterom, R., Oskam, R., Bolhuis, R. L., Stoter, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033917/
https://www.ncbi.nlm.nih.gov/pubmed/7577483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033917/
https://www.ncbi.nlm.nih.gov/pubmed/7577483

Ejemplares similares